ArticleBMC cancer2022

Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study.

Wen Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.